Page 3 - Analyst Event News Today

Onto Innovation Inc. today invites registration for its Company sponsored analyst event on June 1, 2023 at the New York Stock Exchange, New York, New York. If you plan to attend in person, please... | May 11, 2023

First quarter 2023 revenues of $1.9 billion; GAAP net income of $79 million and GAAP diluted EPS of $0.19Company in negotiations for new orders for fall of 2023 in U.S., Japan, and EU, in addition to reiterating

Company to share preliminary safety and efficacy data from ongoing Phase 1/2 trial of OCU400 for the treatment of retinitis pigmentosa and Leber congenital amaurosisMALVERN, Pa., April 11, 2023 --... | April 11, 2023

Fourth quarter 2022 revenues of $5.1 billion; GAAP net income of $1.5 billion and GAAP diluted EPS of $3.61Full-year 2022 revenues of $19.3 billion; GAAP net income of $8.4 billion and GAAP diluted EPS

16.02.2023 - - Rapid, significant, and sustained increase in plasma pyrophosphate (PPi) observed and encouraging patient reported outcome data in all dose cohorts in ENPP1 Deficiency trial - - Rapid and significant increase in PPi observed in all dose cohorts ...

Operator: Good morning, and welcome to Brunswick Corporations Fourth Quarter and Full-year 2022 Earnings Conference Call.

COVID-19 vaccine sales for 2022 approximately $18.4 billion (unaudited)Reiterating 2023 expected minimum COVID-19 vaccine sales of approximately $5.0 billion; continue to expect additional contracts for

/PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced...

SAN FRANCISCO, Dec. 5, 2022 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced that it will host an investor and analyst event on ...

Third quarter 2022 revenues of $3.4 billion; GAAP net income of $1.0 billion and GAAP diluted EPS of $2.53Revenue from advance purchase agreements for anticipated delivery in 2022 expected to be $18 to